VaxFact.net
🦠

MMR Vaccine

Measles · Mumps · Rubella (German measles) · Congenital Rubella Syndrome

Measles has an R0 of 12–18, making it the most contagious vaccine-preventable disease. Pre-vaccine USA: 3–4 million cases and 400–500 deaths annually. Measles causes pneumonia (leading killer), encephalitis (1 in 1,000), and Subacute Sclerosing Panencephalitis (SSPE) — a fatal progressive brain disease occurring years after infection. Rubella during pregnancy causes Congenital Rubella Syndrome — deafness, blindness, heart defects.

📅
55+ yrs
Years in Use
💉
Over 500 million doses worldwide
Doses Administered
🛡️
99% vs severe disease
Effectiveness
👶
12–15 months & 4–6 years (2-dose series)
Age Window

Overall Benefit Score

96/ 100
Strong Recommendation

Default scenario · 12-month-old · US community (92% vax rate)

Score for your child →
Strong Recommendation

For your child's situation, the evidence strongly supports this vaccine. The disease risk is significant and the vaccine provides substantial protection with a well-established safety record.

📊 Evidence Scores

Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).

Net BenefitBenefit minus risk, weighted by exposure probability
96
Exposure RiskLikelihood of encountering the disease
99
Disease ConsequenceSeverity of outcomes if disease is acquired
100
Vaccine BenefitProtection provided against disease and death
99
Vaccine HarmRisk from the vaccine itself (adverse events)
33
Evidence ConfidenceQuality and consensus of the scientific evidence
97

🦠 Disease Burden

Measles has an R0 of 12–18, making it the most contagious vaccine-preventable disease. Pre-vaccine USA: 3–4 million cases and 400–500 deaths annually. Measles causes pneumonia (leading killer), encephalitis (1 in 1,000), and Subacute Sclerosing Panencephalitis (SSPE) — a fatal progressive brain disease occurring years after infection. Rubella during pregnancy causes Congenital Rubella Syndrome — deafness, blindness, heart defects.

🔄
Measles: airborne, extremely contagious — infectious particles remain in the air for 2 hours after an infected person leaves a room. R0 = 12–18. Mumps: respiratory droplets. Rubella: respiratory droplets.
Transmission
very-high
Outbreak Potential
🏥
25% of infected
Hospitalization Rate
⏱️
8% of infected
Long-term Complications
📈
2200 per 100,000/yr
Incidence (unvaccinated)
📉
11 per 100,000/yr
Incidence (vaccinated)
Quality of Life Impact

Measles causes 'immune amnesia' — destroying immunity memory cells and increasing vulnerability to other infections for 2–3 years post-recovery. Children with measles encephalitis have a 25% mortality rate and 25–30% permanent neurological disability among survivors. SSPE is 100% fatal, typically 7–10 years post-measles. Congenital rubella causes deaf-blindness and intellectual disability.

🛡️ Vaccine Effectiveness

🦠
97%
Against Infection
🏥
99%
Against Severe Disease
💚
99.5%
Against Death
Waning Immunity

Two doses provide lifelong immunity for the vast majority. A small percentage (<3%) of vaccinated individuals have primary or secondary vaccine failure. Population immunity >95% required to maintain herd protection against measles.

Breakthrough Infections

Measles outbreaks (e.g., Disneyland 2015, NYC 2019) have almost exclusively occurred in unvaccinated communities or communities with vaccination rates <93–95%.

⚠️ Adverse Events & Side Effects

All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.

Common Side Effects

Injection site pain
Less common than for injectable bacterial vaccines
20,000 / 100k
per dose
Fever 5–12 days post-vaccination
Due to attenuated measles replication; peaks day 6–12
5,000 / 100k
per dose
Mild rash (measles-like)
Occurs 5–12 days post-dose 1; not contagious
5,000 / 100k
per dose
Immune Thrombocytopenia (ITP)
~1 per 25,000–40,000 doses. Temporary low platelet count causing bruising. Usually self-resolving; ~6% require treatment.
40 / 100k
per dose
Febrile seizure
~1 per 3,000 doses (dose 1). Timing: days 6–14. No long-term neurological consequences in controlled studies.
25 / 100k
per dose

Rare Serious Events

Anaphylaxis
~3.5 per million doses. Typically within 30 minutes.
3.5 / 100k
per dose
Encephalitis (acute)
~1 per 1,000,000 doses vs. 1 in 1,000 from wild measles infection — 1,000x safer.
0.1 / 100k
per dose
SSPE from vaccine strain
Theoretical; no confirmed cases of SSPE from vaccine strain. Wild measles SSPE risk: ~1 in 10,000 infections.
0.007 / 100k
per dose

📅 Vaccine Schedule

Dosing Schedule
112–15 months
24–6 years
Key Info
Minimum interval
4 weeks between doses (minimum 28 days)
Can co-administer with
Varicella, DTaP, HepA, HepB, Meningococcal
Catch-Up Notes

Unvaccinated children and adults: 2 doses 28 days apart. International travel: infants 6–11 months get 1 dose; re-vaccinate at 12–15 months and 4–6 years.

⚖️ Benefits vs. Considerations

✓ Benefits

  • 55 years of safety data — the longest record of any combination pediatric vaccine
  • The largest, most rigorous vaccine safety study ever conducted (Hviid 2019: 650,000 children) found no autism signal
  • Measles immune amnesia means unvaccinated children are vulnerable to many diseases simultaneously post-infection
  • SSPE is 100% fatal — the vaccine eliminates this risk entirely
  • Protects pregnant contacts and their unborn children from congenital rubella syndrome
  • Measles is so contagious (R0=12–18) that even modest drops in coverage cause large outbreaks
  • Rubella elimination has nearly eradicated congenital rubella in vaccinated populations

↕ Considerations

  • The Wakefield 1998 fraud created lasting vaccine hesitancy that still affects coverage rates globally
  • Febrile seizures occur in ~1 per 3,000 doses (real, though typically benign)
  • Cannot be given to immunocompromised children — this is an important clinical caveat
  • MMR + varicella (MMRV) combination has 2x febrile seizure rate vs. giving vaccines separately
  • Contains gelatin stabilizer — relevant for families with religious dietary restrictions

🔬 What Some Researchers Question

These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.

  • The Wakefield (1998) MMR-autism claim has been thoroughly refuted by 30+ large studies and over 1.2 million children. Wakefield lost his medical license for research fraud. This is a case study in how a retracted paper caused lasting harm — cited here to document the history, not the science.
  • Some virologists raise questions about whether herd immunity thresholds calculated for measles (>95%) adequately account for waning immunity in previously vaccinated adults, who now represent a growing susceptible subpopulation (Dine et al., 2004).
  • Critics note that mumps VE has historically been lower (~88%) than measles VE, and college campus outbreaks in vaccinated populations raise questions about mumps component durability (CDC 2019 — Mumps Cases and Outbreaks).

🌫️ Scientific Uncertainties

Honest acknowledgment of what we don't yet know with confidence.

  • The exact mechanism of measles immune amnesia and its full long-term consequences are still being characterized
  • Whether primary and secondary vaccine failure rates are sufficient to eventually require a 3rd dose in adult years
  • Whether the rubella component immunity duration is sufficient for all women of childbearing age vaccinated in childhood

🌍 International Policy Comparison

How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.

US
United States✓ Recommended
12–15m, 4–6y
Universal 2-dose schedule since 1989. Measles eliminated from USA in 2000 (though outbreaks occur in unvaccinated communities).
GB
United Kingdom✓ Recommended
12–13m, 3y4m
MMR controversy (Wakefield 1998) caused coverage to fall; subsequent restoration of confidence required sustained public health effort.
AU
Australia✓ Recommended
12m, 18m
No More Measles campaigns; measles endemic transmission eliminated.
FI
Finland✓ Recommended
14–18m, 6y
Finland achieved measles elimination in 1994 — one of the first countries. Zero endemic transmission since.
JP
Japan✓ Recommended
12–23m, 5–6y
Japan eliminated endemic measles in 2015 after strengthening its 2-dose program.

Brand Names

M-M-R IIPriorixMMRV (with varicella)

Evidence Quality

Years of Study97/100
Long-Term Safety95/100
Evidence Confidence97/100
In use since1971

Key Sources

Demicheli et al. — Vaccines for MMR in children (Cochrane)
META-ANALYSIS · 2020 · Multi-country · high confidence
Jain et al. — Autism and MMR in >95,000 children (JAMA Pediatrics)
COHORT · 2015 · USA · high confidence
Hviid et al. — MMR and autism (Annals of Internal Medicine)
COHORT · 2019 · Denmark · high confidence
WHO position paper on measles vaccines
REVIEW · 2017 · Global · high confidence
Madsen et al. — MMR and autism in 530,000 Danish children (NEJM)
COHORT · 2002 · Denmark · high confidence
🎯

Get your personalized score

Adjust for your child's age, daycare, travel plans, and community vaccination rate to see a customized risk-benefit analysis.

Open Score Calculator →